 |
 |
 |
 |
 |
 |
ECI Biotech CEO and Founder Dr. Mitchell Sanders will moderate and speak at MDEXEC
Annual Conference May 20 – 21 in Minneapolis, MN.DATELINE: Minneapolis, MN — May 19, 2010 — ECI Biotech is pleased to announce that Dr. Mitchell Sanders, ECI’s CEO and Founder, will moderate and speak at the MDDEXEC 2nd Annual Sales and Marketing Excellence 2010 conference on May 20th - 21st in Minneapolis, MN. The MDDEXEC (Medical Device and Diagnostics Executive) conference is the only sales and marketing event for the device and diagnostics community
Headquartered in Worcester, MA, ECI Biotech is a premier developer of low cost and rapid diagnostics trademarked as ExpressDetect that has 2 products going to launch in 2011 including a dressing sensor and a rapid point of care diagnostic that are targeted at prognosing chronic and acute wound infections.
Dr. Sanders’ MDDEXEC presentation will focus on how small and medium size enterprises (SME) can be more resourceful with their marketing budget by utilizing advances in technology and maximizing their human capital potential to increase sales on a global scale. Highlights will feature:
• ECI Biotech’s Marketing B2B Strategies
• Paradigm Shifts in Sales and Marketing based on technology advances
• Using iPhones to as weapon to monitor everything from clinical trial performance to Sales and Marketing traction.
MDDEXEC
MDDEXEC (Medical Device and Diagnostics Executive) annual conference is designed as a senior-level event for sales and marketing executives in the device and diagnostic field. Featuring industry-led keynote presentations, case studies, panel debates and high-level networking, the conference offers many opportunities for executives striving to make the most out of cutting-edge and alternative sales & marketing innovation best-practices.
ECI Biotech
Founded in 1998, ECI Biotech is a premier developer of low cost and rapid diagnostics trademarked as ExpressDetect. ECI's first diagnostic products going to launch in 2011 are targeted at prognosing chronic and acute wound infections and include a dressing sensor and a rapid point of care diagnostic. With 18 patents pending and three patents issued, ECI currently has several corporate partnerships with industry leaders in both consumer and professional healthcare
ECI’s target markets for its products include: feminine care, wound care, oral care, and hospital infection control. ECI Biotech's product pipeline includes a diagnostic sensor for urinary tract infections, as well as advanced wound care systems that provide early warning of emergent infections and promote healing.
ECI Biotech’s headquarters are located at 85 Prescott Street, in Worcester, Massachusetts.
For additional information please contact Dr. Mitchell Sanders at sanders@ecibiotech.com, call 508-752-2209, or visit www.ecibiotech.com.